Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
Holderfield M, Deuker MM, McCormick F, McMahon M. Holderfield M, et al. Nat Rev Cancer. 2014 Jul;14(7):455-67. doi: 10.1038/nrc3760. Nat Rev Cancer. 2014. PMID: 24957944 Free PMC article. Review.
RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. Holderfield M, et al. Cancer Cell. 2013 May 13;23(5):594-602. doi: 10.1016/j.ccr.2013.03.033. Cancer Cell. 2013. PMID: 23680146
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D. Holderfield M, et al. Cancer Res. 2014 Apr 15;74(8):2238-45. doi: 10.1158/0008-5472.CAN-13-1065-T. Epub 2014 Feb 12. Cancer Res. 2014. PMID: 24523442
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
Holderfield M, Nagel TE, Stuart DD. Holderfield M, et al. Br J Cancer. 2014 Aug 12;111(4):640-5. doi: 10.1038/bjc.2014.139. Epub 2014 Mar 18. Br J Cancer. 2014. PMID: 24642617 Free PMC article. Review.
K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling.
Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. Wang MT, et al. Among authors: holderfield m. Cell. 2015 Nov 19;163(5):1237-1251. doi: 10.1016/j.cell.2015.10.041. Cell. 2015. PMID: 26590425 Free article.
Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit.
Ritt DA, Abreu-Blanco MT, Bindu L, Durrant DE, Zhou M, Specht SI, Stephen AG, Holderfield M, Morrison DK. Ritt DA, et al. Among authors: holderfield m. Mol Cell. 2016 Dec 1;64(5):875-887. doi: 10.1016/j.molcel.2016.10.029. Epub 2016 Nov 23. Mol Cell. 2016. PMID: 27889448 Free PMC article.
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M. Rabara D, et al. Among authors: holderfield m. Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22122-22131. doi: 10.1073/pnas.1908353116. Epub 2019 Oct 14. Proc Natl Acad Sci U S A. 2019. PMID: 31611389 Free PMC article.
Progress in targeting RAF kinases for cancer therapy.
Turbyville TJ, Holderfield M. Turbyville TJ, et al. Per Med. 2015 Jun;12(3):183-186. doi: 10.2217/pme.15.1. Per Med. 2015. PMID: 29771643 No abstract available.
Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions.
Gillette WK, Esposito D, Abreu Blanco M, Alexander P, Bindu L, Bittner C, Chertov O, Frank PH, Grose C, Jones JE, Meng Z, Perkins S, Van Q, Ghirlando R, Fivash M, Nissley DV, McCormick F, Holderfield M, Stephen AG. Gillette WK, et al. Among authors: holderfield m. Sci Rep. 2015 Nov 2;5:15916. doi: 10.1038/srep15916. Sci Rep. 2015. PMID: 26522388 Free PMC article.
21 results
Jump to page